Experimental drug aims to tame COVID-19's dangerous inflammation
NCT ID NCT04469621
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 20 times
Summary
This early-stage study tested an experimental drug called SAR443122 in 68 adults hospitalized with severe COVID-19. The goal was to see if the drug could safely reduce harmful inflammation, measured by a blood marker called C-reactive protein. Participants received either the drug or a placebo, and researchers tracked their oxygen needs and recovery. The study is complete, but results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number 0320001
Caba, 1430, Argentina
-
Investigational Site Number 0760001
São José do Rio Preto, 15090-000, Brazil
-
Investigational Site Number 0760002
São Paulo, 04321-120, Brazil
-
Investigational Site Number 0760003
Porto Alegre, 90035 003, Brazil
-
Investigational Site Number 1520001
Santiago, 750-0691, Chile
-
Investigational Site Number 1520002
Talca, 3460001, Chile
-
Investigational Site Number 1520003
Santiago, 8900085, Chile
-
Investigational Site Number 4840001
Monterrey, 64460, Mexico
-
Investigational Site Number 6430001
Moscow, 111539, Russia
-
Investigational Site Number 6430002
Moscow, 123182, Russia
Conditions
Explore the condition pages connected to this study.